U.S. Health Secretary Robert F. Kennedy Jr. emphasized during an interview on Fox News’ Special Report with Bret Baier that the Trump administration has no plans to restrict access to vaccines. Kennedy clarified that Americans who want vaccines will continue to have them, countering concerns about possible changes to national health policy.
Addressing recent speculation, Kennedy underscored that the administration supports medical freedom while maintaining access to essential healthcare. He stated that while the government may evaluate certain programs, it will not remove the option for citizens who choose vaccination. This assurance comes at a time when vaccine policy remains a sensitive and highly debated topic in the U.S.
Kennedy’s remarks are intended to reassure families, healthcare providers, and public health advocates who fear potential shifts in vaccine distribution. He noted that the government recognizes the importance of vaccines in preventing disease outbreaks and protecting vulnerable populations. At the same time, the administration aims to respect individual choice, striking a balance between public health priorities and personal freedoms.
The Health Secretary’s statement aligns with broader efforts to ensure transparency and trust between the government and the public. By directly addressing concerns on a national platform, Kennedy sought to reaffirm that vaccines will remain readily available for those who want them, without interference or restriction.
As debates over vaccine policy continue, Kennedy’s comments highlight the administration’s commitment to both accessibility and choice, assuring Americans that their healthcare decisions will remain in their own hands.


Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding
Israel Intensifies Gaza Airstrikes Amid Ceasefire Tensions
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
More Than 100 Venezuelan Political Prisoners Released Amid Ongoing Human Rights Scrutiny
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas
Kevin Warsh’s Fed Nomination Raises Questions Over Corporate Ties and U.S.–South Korea Trade Tensions
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 



